EMA Assessing 'Slightly' Raised Heart Attack Risk With Two COVID-19 Vaccines
Moderna's Spikevax Linked To Flare-Up Of Capillary Leak Syndrome
Executive Summary
The EU’s latest safety report on coronavirus vaccines looks at the risk of myocardial infarction, pulmonary embolism, thrombosis and capillary leak syndrome following vaccination.
You may also be interested in...
EMA Assessing Variant-Adapted Spikevax, Probes Heart Inflammation With Nuvaxovid
A rolling review of an adapted version of Moderna’s COVID-19 vaccine Spikevax aimed at variants of SARS-CoV-2 has begun at the European Medicines Agency. The EMA has also given an update on its latest vaccine safety reviews, including reports of heavy menstrual bleeding with Spikevax and Comirnaty.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.